<DOC>
	<DOCNO>NCT00940524</DOCNO>
	<brief_summary>This research study people specific type leukemia call Philadelphia chromosome positive acute lymphoblastic leukemia ( type patient ) . The investigator plan give combination 3 drug ( dasatinib , mitoxantrone , cytarabine ) first part chemotherapy ( call Induction ) . The investigator previously show combination mitoxantrone cytarabine effective kind leukemia . The purpose study establish safe dose range dasatinib combination standard induction chemotherapy base side effect . If possible , trial also give u idea well combination might work treat leukemia . Previous study show dasatinib produce response give alone kind leukemia . By use dasatinib together chemotherapy , investigator believe kill even leukemia cell either treatment alone . The investigator initially treat patient low dose dasatinib monitor side-effects . If initial group patient able tolerate low-dose dasatinib , future patient receive high dos dasatinib . Mitoxantrone cytarabine chemotherapy standard therapy investigator ' institution patient 's leukemia combination dasatinib chemotherapy new investigational study .</brief_summary>
	<brief_title>Induction Therapy With Cytarabine , High-Dose Mitoxantrone Dasatinib Patients With Philadelphia-Chromosome Positive ( Ph+ ) Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Previously untreated treated adult patient ( &gt; = 18 year old ) diagnosis : Philadelphiachromosome positive acute lymphoblastic leukemia Lymphoid blast crisis know chronic myelogenous leukemia NOTE : Patients must evidence ( 9 ; 22 ) leukemic cell base chromosomal molecular analysis . NOTE : The diagnosis must confirm pathology department MSKCC . NOTE : It recognize newly diagnose patient may start therapy cytarabine highdose mitoxantrone ( standard care institution treat adult ALL ) prior identification ( 9 ; 22 ) leukemic cell . These patient remain eligible participation study evaluable response possible start treatment dasatinib within 30 day receive induction chemotherapy . Patients adequate hepatic function ( AST ALT &lt; = 2.5 institutional ULN , bilirubin &lt; = 2.0 mg/dl ) . Patients adequate renal function ( creatinine &lt; = 2.0 mg/dl creatinine clearance &gt; 50 ml/min ) . Patients LVEF &gt; = 50 % . Karnofsky performance status &gt; = 20 % . Ability take oral medication ( dasatinib must swallow whole ) . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test ( sensitivity &gt; = 25IU HCG/L ) within 72 hour prior start study drug administration . Persons reproductive potential must agree use utilize adequate method contraception throughout treatment least 6 month study drug stop . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . concomitant Medications : Patient agree discontinue St. Johns Wort receive dasatinib therapy ( discontinue St. Johns Wort least 5 day start dasatinib ) ; Patient agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . Signed informed consent , indicate investigational nature study , within 30 day treatment initiation , require . Female patient pregnant lactate . Women men childbearing age use effective contraception . Patients uncontrolled active infection . Patients receive systemic chemotherapy . Patients must prior antileukemic therapy least 2 week ( hydroxyurea consider acceptable ) . NOTE : Patients previously receive combination therapy cytarabine , highdose mitoxantrone dasatinib exclude trial . All prior therapy allow , include prior tyrosine kinase inhibitor usage . Prior dasatinib use allow ( single agent combination therapy , combination therapy cytarabine highdose mitoxantrone ) . Concomitant active secondary malignancy require treatment ( squamous cell basal cell carcinoma skin ) . Concurrent medical condition may increase risk toxicity , include : grade â‰¥ 2 pleural pericardial effusion . Cardiac Symptoms ; follow consider exclusion : Uncontrolled angina , congestive heart failure MI within ( 6 month ) . Diagnosed congenital long QT syndrome . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) . Subjects hypokalemia hypomagnesemia correct prior dasatinib administration . History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) . Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) . Ongoing recent ( &lt; = 3 month ) significant gastrointestinal bleeding Concomitant Medications , follow consider exclusion : Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) quinidine , procainamide , disopyramide amiodarone , sotalol , ibutilide , dofetilide erythromycin , clarithromycin chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>ALLOPURINOL</keyword>
	<keyword>CARMUSTINE ( BCNU )</keyword>
	<keyword>CYCLOPHOSPHAMIDE ( CYTOXAN )</keyword>
	<keyword>CYTARABINE ( ARA-C )</keyword>
	<keyword>DACTINOMYCIN</keyword>
	<keyword>DASATINIB</keyword>
	<keyword>DEXAMETHASONE</keyword>
	<keyword>DOXORUBICIN/ADRIAMYCIN</keyword>
	<keyword>ETOPOSIDE ( VP-16 )</keyword>
	<keyword>MERCAPTOPURINE</keyword>
	<keyword>METHOTREXATE</keyword>
	<keyword>MITOXANTRONE</keyword>
	<keyword>PEGASPERGASE</keyword>
	<keyword>VINCRISTINE</keyword>
</DOC>